COSMO Pharmaceuticals N.V. (0RGI) Price & Analysis

15 Followers

0RGI Stock Chart & Stats

CHF57.22

-CHF0.18(-0.28%)

At close: Jul 27 4:00 PM EDT

CHF57.22

-CHF0.18(-0.28%)

Day’s Range― - ―

52-Week RangeCHF51.70 - CHF129.60

Previous CloseN/A

Volume48.83K

Average Volume (3M)3.86K

Market Cap

CHF941.23M

Enterprise ValueCHF963.95

Total Cash (Recent Filing)CHF195.28M

Total Debt (Recent Filing)CHF4.33M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Mar 24, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.46%

Share Statistics

EPS (TTM)-0.38

Shares Outstanding17,543,522

10 Day Avg. Volume2,659

30 Day Avg. Volume3,864

Financial Highlights & Ratios

PEG Ratio4.78

Price to Book (P/B)3.74

Price to Sales (P/S)17.21

P/FCF Ratio-113.83

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF115.00

Price Target Upside100.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)0.12

Revenue Forecast (FY)CHF106.67M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetMinimal leverage and substantial equity provide Cosmo with financial resilience and flexibility to fund development, partnerships, or commercialization without relying heavily on borrowing. This strong capital position can help the company absorb operating volatility while preserving strategic options.

Partnering And Licensing ModelThe combination of proprietary product sales and licensing partnerships gives Cosmo multiple routes to monetize its gastroenterology and endoscopy portfolio. Partners may also fund selected development or commercialization activities, potentially extending reach while reducing some internal execution demands.

Demonstrated Profit And Cash GenerationCosmo has demonstrated that its portfolio can produce substantial earnings and cash generation in a strong operating year. Although performance later weakened, this history indicates underlying commercial potential and provides evidence that the business can generate meaningful internal funding when conditions are favorable.

Bears Say

Sharp Revenue ContractionThe steep year-on-year revenue decline signals substantial instability in Cosmo’s current operating run-rate. A smaller revenue base can reduce operating leverage, limit reinvestment capacity, and make future earnings more dependent on successful product performance, partner activity, or milestone timing.

Negative Operating Cash FlowThe shift from strong cash generation to operating and free cash burn weakens the quality and sustainability of recent financial performance. Continued negative cash flow would require Cosmo to draw on its balance sheet or alter investment plans, despite its otherwise conservative capital structure.

Volatile ProfitabilityRepeated swings between strong profits and losses indicate limited consistency in Cosmo’s earnings profile. Negative EBIT and net margins in 2025 suggest that the company is currently unable to convert its revenue base reliably into profits, making medium-term performance less predictable.

COSMO Pharmaceuticals N.V. News

Cosmo’s GI Genius AI System Boosts Adenoma Detection in Major VA Study

COSMO Pharmaceuticals N.V. ( ($CH:CMHC) ) has shared an update. Cosmo has reported landmark real-world results for its...

7d ago

Cosmo Pharmaceuticals to Change SIX Ticker to CMHC, Aligning Brand With Health-Focused Strategy

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has provided an announcement. Cosmo Pharmaceuticals N.V. will change its ticker symbol...

2M ago

Cosmo lifts recurring revenues and advances dermatology and GI pipelines

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) just unveiled an announcement. Cosmo reported strong first-half 2026 results, with recurring...

2M ago

Cosmo sets date for 2026 half-year results and investor webcast

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has issued an announcement. Cosmo Pharmaceuticals will publish its 2026 half-year results...

3M ago

Cosmo accelerates European rollout of first-in-class acne drug Winlevi

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has issued an update. Cosmo Pharmaceuticals has expanded the European rollout of...

4M ago

Cosmo and Glenmark roll out first-in-class acne drug Winlevi across key European markets

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has shared an announcement. Cosmo Pharmaceuticals’ dermatology unit Cassiopea has developed Winlevi,...

4M ago

Cosmo completes Phase II recruitment for novel ulcerative colitis therapy

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) just unveiled an announcement. Cosmo Pharmaceuticals has completed patient recruitment for a...

4M ago

Cosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cosmo Pharmaceuticals (CMOPF) to CHF 160 from CHF 130 and...

5M ago

Cosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) just unveiled an announcement. Cosmo Pharmaceuticals has reported positive 12‑month Phase III...

6M ago

Cosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend

COSMO Pharmaceuticals N.V. ( ($CH:COPN) ) has shared an announcement. Cosmo Pharmaceuticals reported that shareholders approved all agenda...

6M ago

0RGI FAQ

What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?

COSMO Pharmaceuticals N.V. lowest share price was CHF51.70 and its highest was CHF129.60 in the past 12 months.

What is COSMO Pharmaceuticals N.V.’s market cap?

COSMO Pharmaceuticals N.V.’s market cap is CHF941.23M.

When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?

COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 177 days.

How were COSMO Pharmaceuticals N.V.’s earnings last quarter?

COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -CHF0.263 earnings per share for the quarter, missing the consensus estimate of CHF0 by -CHF0.263.

Is COSMO Pharmaceuticals N.V. overvalued?

According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does COSMO Pharmaceuticals N.V. pay dividends?

COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.928 which represents an annual dividend yield of 3.46%. See more information on COSMO Pharmaceuticals N.V. dividends here

What is COSMO Pharmaceuticals N.V.’s EPS estimate?

COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does COSMO Pharmaceuticals N.V. have?

COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.

What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?

COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.263 in its last earnings report, missing expectations of CHF0. Following the earnings report the stock price went up 7.194%.

Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?

Currently, no hedge funds are holding shares in GB:0RGI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

COSMO Pharmaceuticals N.V.

Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

COSMO Pharmaceuticals N.V. (0RGI) Earnings & Revenues

Historic Earnings Reports

0RGI Stock 12 Month Forecast

Average Price Target

CHF115.00

▲(100.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"54":"CHF54","121":"CHF121","70.75":"CHF70.8","87.5":"CHF87.5","104.25":"CHF104.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[54,70.75,87.5,104.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.627,60.57876923076923,65.53053846153847,70.4823076923077,75.43407692307693,80.38584615384616,85.33761538461539,90.28938461538462,95.24115384615385,100.19292307692308,105.14469230769231,110.09646153846154,115.04823076923077,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.627,60.194153846153846,64.7613076923077,69.32846153846154,73.89561538461538,78.46276923076923,83.02992307692307,87.59707692307693,92.16423076923077,96.73138461538461,101.29853846153847,105.86569230769231,110.43284615384616,{"y":115,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.627,59.809538461538466,63.99207692307692,68.1746153846154,72.35715384615385,76.53969230769232,80.72223076923078,84.90476923076923,89.08730769230769,93.26984615384616,97.45238461538463,101.63492307692309,105.81746153846154,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.748,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.953,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.123,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.807,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.053,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.181,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.263,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.437,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.425,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.436,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.366,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.181,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.627,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >